EYLEA® extended dosing can reduce the treatment burden for you and your patients1,2

57% of patients had a next intended injection interval of ≥12 weeks in the ALTAIR study at the end of Year 13,a

ALTAIR: 57% Next Intended Injection Interval ≥12 weeks
  • Up to 41% of patients had a next intended injection interval of 16 weeks3,a

a The ‘next intended injection interval’ was defined as the time between the last injection and the next scheduled injection at the final study visit at Week 52.

References

  1. Heier JS, Brown DM, Chong V, et al. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology. 2012;119(12):2537-2548.
  2. EYLEA® (aflibercept solution for injection) Summary of Product Characteristics. Berlin, Germany: Bayer Pharma AG; July 2018.
  3. Okada AA, Takahashi K, et al. Use of Intravitreal Aflibercept Treat-and-Extend Dosing for Wet Age-Related Macular Degeneration: 52-Week ALTAIR Results. Poster presented at the American Academy of Ophthalmology (AAO) Congress New Orleans, LA, November 11–14, 2017. Available from: https://aao.scientificposters.com/epsWelcome.cfm?CFID=6335346&CFTOKEN=47c8b80ef1e0478c-3912E1EF-E986-D0BE-7EE9563148B676EF.